Results 201 to 210 of about 5,706,732 (263)

Human Fibroblast–Myeloid Cell Tissue Atlas Across the Lungs, Synovium, Skin, and Heart

Arthritis &Rheumatology, EarlyView.
Objective The availability of single‐cell RNA sequencing (scRNAseq) data in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald, Katerina Apostolopoulou, Olympia Hardy, Melpomeni Toitou, Gabriela Kania, Przemyslaw Blyszczuk, Raphael Micheroli, Thomas D. Otto, Mariola Kurowska‐Stolarska, Caroline Ospelt   +9 more
wiley   +1 more source

Interstitial Lung Disease in a Dental Technician Diagnosed Through an Integrated Multidisciplinary Approach. [PDF]

Med Lav
Giulianelli G, Maggioni G, Daverio M, Polverosi R, Della Barbera M, Mason P, Spagnolo P, Basso C, Calabrese F, Rizzo S, Balestro E.   +10 more
europepmc   +1 more source

Comparative Transcriptional Profiling of Key Macrophage and Fibroblast Subpopulations in Rheumatoid Arthritis–Associated Lung Disease

Arthritis &Rheumatology, EarlyView.
Objective Rheumatoid arthritis (RA) often involves extra‐articular complications, including interstitial lung disease (ILD) and/or pulmonary nodules. Transcriptomic profiling of lung tissue provides the opportunity to directly assess cell‐specific gene expression and corresponding pathway activation in different types of rheumatoid lung disease ...
Tracy Tabib, Ogechukwu Ezenwa, Joshua Sciurba, Eleanor B. Valenzi, John Sembrat, Brittany Cody, Jishnu Das, Robert Lafyatis, Dana P. Ascherman   +8 more
wiley   +1 more source

Idiopathic inflammatory myopathy-related interstitial lung disease patients present to pulmonology: a tertiary center experience. [PDF]

Ann Am Thorac Soc
Davis AE, Wilson D, Ludtke EA, De Andrade JA, Annapureddy N, Young-Glazer J, Olajide AA, Dudenhofer RB, Hewlett JC, Wilfong EM, MYSTIC Investigators.   +10 more
europepmc   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

Arthritis &Rheumatology, EarlyView.
Objective TypeI interferonopathies are heterogeneous diseases driven by dysregulated type I interferon (IFN‐I) signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. The aim of this study was to characterize the clinical, immunologic, genetic, molecular profiles of patients with suspected ...
Ismail Yaz, Seza Ozen, Hacer Neslihan Bildik, Canberk Ipsir, Dilara Unal, Saliha Esenboga, Begum Cicek, Mehmet Emin Seker, Fatima Aerts‐Kaya, Seher Sener, Mehmet Orhan Erkan, Hanife Avci, Deniz Cagdas, Ilhan Tezcan   +13 more
wiley   +1 more source

Diagnostic methods of rheumatoid arthritis-associated interstitial lung disease: a systematic review. [PDF]

Rheumatol Int
Lewandowska-Polak A, Brzezińska O, Krawiec P, Skalska U, Krajewska-Włodarczyk M, Stajszczyk M, Kwiatkowska B, Żuber Z, Kowal-Bielecka O, Batko B, Makowska JS.   +10 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Interstitial Lung Disease in Children: Rare Genetic Variants Beyond Surfactant Dysfunction. [PDF]

Pediatr Pulmonol
Tabakçı SÖ, Akyan Soydaş ŞS, Tuğcu GD, Cinel G, Sağdıç AC, Özçelik U, Can Oksay S, Korkmaz Ç, Zirek F, Kekeç H, Gülen F, Hangül M, Özsezen B, Altıntaş DU, Çağlar HT, Başaran AE, Uyan ZS, Özdemir A, Ramaslı Gürsoy T, Yalçın E, Emiralioğlu N, Girit S, Kılınç AA, Çobanoğlu N, Şişmanlar Eyüboğlu T, Pekcan S, Gökdemir Y, Oğuz B, Orhan D, Ceylan AC, Kiper N.   +30 more
europepmc   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source

Flecainide-Induced Interstitial Lung Disease: A Case Report and Review of the Literature. [PDF]

Clin Case Rep
Jenkins E, McGinty J, Skinner B.
europepmc   +1 more source